You might also like
Danaher Corporation is a global conglomerate that operates in the fields of biotechnology, life sciences, and diagnostics. The company provides a wide range of products and services, including equipment, consumables, and software, primarily sold on a recurring basis . Danaher emphasizes innovation and strategic acquisitions to enhance its portfolio and maintain competitive advantages in its served markets .
- Biotechnology - Focuses on bioprocessing and discovery, offering equipment, consumables, and services used in the development and manufacture of biological medicines, including therapies like insulin, vaccines, and novel cell and gene therapies .
- Life Sciences - Provides instruments, consumables, and software for genomics and disease research, as well as products for filtering contaminants from liquids and gases .
- Diagnostics - Offers clinical instruments and services used in disease diagnosis and treatment decisions .
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Brian W. Ellis Executive | Senior Vice President - General Counsel | None | General Counsel since January 2016; no additional details on prior roles or external affiliations provided. | |
Christopher P. Riley Executive | Executive Vice President | None | Joined DHR in 2017; held leadership roles in Life Sciences and Diagnostics subsidiaries; became EVP in January 2024. | |
Daniel A. Raskas Executive | Senior Vice President - Corporate Development | None | Joined DHR in 2010; no additional details on prior roles or external affiliations provided. | |
Georgeann F. Couchara Executive | Senior Vice President - Human Resources | None | Joined DHR in 2019; focuses on talent development, DE+I, and organizational development; instrumental in Veralto spin-off. | |
Jose-Carlos Gutierrez-Ramos Executive | Senior Vice President and Chief Science Officer | None | Joined DHR in December 2020; previously held leadership roles at AbbVie and Repertoire Immune Medicines; advancing DHR's AI and data strategy. | |
Matthew R. McGrew Executive | Executive Vice President and CFO | None | CFO since January 2019; no additional details on prior roles or external affiliations provided. | |
Rainer M. Blair Executive | President and Chief Executive Officer | None | Joined DHR in 2010; became CEO in September 2020; instrumental in implementing the Danaher Business System and leading portfolio transformation. | View Report → |
William H. King Executive | Senior Vice President - Strategic Development | Board Member at Veralto Corporation | Joined DHR in 2005; oversees strategic development; designated as a Class I Director for Veralto Corporation. | |
Alan G. Spoon Board | Director | Board Member at Fortive, IAC/InterActiveCorp, and Match Group | Director since 1999; expertise in business strategy, technology trends, and executive compensation; serves on multiple public company boards. | |
Elias A. Zerhouni, M.D. Board | Director | President and Vice Chairman of OPKO Health | Director since 2009; former NIH Director and Sanofi R&D President; expertise in medical technologies and global healthcare. | |
Feroz Dewan Board | Director | CEO of Arena Holdings Management LLC | Director since 2022; CEO of Arena Holdings; previously served on boards of Kraft Heinz and Fortive Corporation. | |
Jessica L. Mega, M.D. Board | Director | None | Director since 2019; co-founder and former Chief Medical and Scientific Officer at Verily Life Sciences; expertise in clinical trials and healthcare innovation. | |
John T. Schwieters Board | Director | Board Member at Veralto Corporation | Director since 2003; chaired DHR's Audit Committee; extensive experience in public accounting, tax, and finance. | |
Linda Filler Board | Director | Board Member at The Carlyle Group | Director since 2005; retired from executive roles at Walgreens and Claire's; extensive experience in retail and consumer goods. | |
Raymond C. Stevens, Ph.D. Board | Director | CEO of Structure Therapeutics | Director since 2017; world-renowned biomedical scientist; expertise in molecular research and drug development; CEO of Structure Therapeutics. | |
Steven M. Rales Board | Chairman of the Board | None | Co-founded DHR in 1983; Chairman since 1984; pivotal in creating the Danaher Business System and driving the company's growth. | |
Teri List Board | Director | Board Member at Microsoft, Visa, and lululemon | Director since 2011; former CFO at Gap Inc., Dick's Sporting Goods, and Kraft Foods; extensive experience in finance and accounting. |
-
Given the persistent challenges in the China market, including volume-based procurement and increasing local competition in bioprocessing and diagnostics, how do you plan to achieve your growth targets and mitigate these headwinds in the coming year?
-
With uncertainties around the China stimulus, ongoing constraints in capital equipment spending, and the gradual recovery in bioprocessing orders, is the expectation of 8% core growth in 2025 realistic, or should investors anticipate a more conservative outlook?
-
Considering that smaller bioprocessing customers, representing 25% of revenues, are still facing funding challenges and slower recovery, how significant is this segment's impact on your overall bioprocessing business, and what strategies are you implementing to support growth here?
-
In light of the low single-digit growth in genomics and continued softness in gene reading among smaller customers, what specific actions are you taking to drive growth and gain market share, especially with the introduction of products like Rapid Genes?
-
Regarding the integration of Abcam, can you provide more detail on its current performance and whether it is meeting your expectations for growth acceleration and cost improvements, given previous concerns about underperformance?
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Multiple Life Sciences Businesses | 2024 | The company acquired multiple Life Sciences businesses, including two for a total of $525 million in cash (net of cash acquired) during the nine‐month period ended September 27, 2024, and one additional business for $12 million in cash (net of cash acquired) during the six‐month period ended June 28, 2024, to complement existing Life Sciences units. |
Abcam plc | 2023 | Danaher entered into a definitive agreement on August 28, 2023, to acquire Abcam plc for approximately $5.7 billion (including assumed indebtedness and net of acquired cash), integrating its protein consumables capabilities into the Life Sciences segment to advance drug discovery and diagnostics; the transaction is expected to close by mid‑2024. |
Multiple Companies Acquisition | 2022 | In 2022, Danaher completed several acquisitions across its segments, starting with a Q1 deal for $13 million in cash (annual sales of $7 million), followed by a first‑half acquisition totaling $77 million in cash and culminating with five acquisitions in the nine‑month period for $304 million in cash, all aimed at broadening capabilities in Life Sciences and Environmental & Applied Solutions. |
Recent developments and announcements about DHR.
Earnings
New Earnings (Q4 2024)
·Jan 29, 2025, 3:59 PMView full earnings summary →Danaher posts 30%+ Q4 bioprocessing order growth and invests $7B to buy back 28M shares, signaling confidence in future gains. Yet 2025 EPS expectations fell, with Diagnostics facing China VBP pressure and Life Sciences starting 2025 down mid-single digits.
8-K Filings
8-K Filing
·Feb 20, 2025, 10:21 PMLeadership ChangesView full 8-K filing →Danaher announced on Feb 20, 2025 that Charles W. Lamanna has been appointed as a non-employee director, serving on the Science & Technology Committee with his term expiring at the 2025 annual meeting. The 2007 Omnibus Incentive Plan now accelerates vesting upon death or disability.